"Piatkowska-Jakubas, B." . . . "Bone Marrow Transplantation" . "Krawczyk-Kulis, M." . "0268-3369" . "RIV/00216224:14110/10:00051241!RIV12-MSM-14110___" . . "Doubek, Michael" . . "auto transplant; ALL; minimal residual disease"@en . "6" . "Mayer, Ji\u0159\u00ED" . "Ribera, J. M." . "45" . . . "Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL" . "7"^^ . "Czerw, T." . . "G\u00F6kbuget, N." . "Holowiecki, J." . "The role of autologous hematopoietic SCT (autoHSCT) in the treatment of high-risk (HR) adult ALL is controversial. In this study, we retrospectively analyzed the results of autoHSCT according to the status of minimal residual disease (MRD) at transplantation, as a joint analysis of the European Study Group for Adult ALL (EWALL). Data on 123 recipients of autoHSCT, aged 31 (16\u201359) years, with B-lineage or T-lineage ALL were included. In a cohort of Ph-negative ALL, the probability of leukemia-free survival at 5 years was higher for patients with MRD o0.1% compared with those with MRD X0.1%. The difference was significant for T-lineage ALL, and a tendency was observed for B-lineage ALL. In a multivariate analysis, adjusted for other potential prognostic factors, high MRD level remained the only independent factor associated with increased risk of failure. We conclude that MRD determines the outcome of autoHSCT in HR adult ALL." . . "Piccaluga, P. P." . "2"^^ . "Dombret, H." . "Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL" . "Kyrcz-Krzemien, S." . . . "The role of autologous hematopoietic SCT (autoHSCT) in the treatment of high-risk (HR) adult ALL is controversial. In this study, we retrospectively analyzed the results of autoHSCT according to the status of minimal residual disease (MRD) at transplantation, as a joint analysis of the European Study Group for Adult ALL (EWALL). Data on 123 recipients of autoHSCT, aged 31 (16\u201359) years, with B-lineage or T-lineage ALL were included. In a cohort of Ph-negative ALL, the probability of leukemia-free survival at 5 years was higher for patients with MRD o0.1% compared with those with MRD X0.1%. The difference was significant for T-lineage ALL, and a tendency was observed for B-lineage ALL. In a multivariate analysis, adjusted for other potential prognostic factors, high MRD level remained the only independent factor associated with increased risk of failure. We conclude that MRD determines the outcome of autoHSCT in HR adult ALL."@en . . "Skotnicki, A. B." . . "Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL"@en . . "Stella-Holowiecka, B." . "10.1038/bmt.2009.308" . "Giebel, S." . "V" . . "14110" . "15"^^ . "[4F47EB718EE6]" . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Hoelzer, D." . "000278573600021" . "Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL"@en . "289992" . "RIV/00216224:14110/10:00051241" . .